drugset
drugset / Trial / NCT03236064

Conversion of Seddon III Nerve Injury to Seddon I/II Nerve Injury

NCT03236064 ↗

Phase 1 Unknown 10 enrolled WellSpan Health Neuraptive Therapeutics Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and efficacy of PEG 3350 for use in nerve repair.

Timeline

Start
2016-05
Primary completion
2024-05
Completion
2024-05

Drugs

EvaluationDrugModalityDoseRoute
Subject polyethylene glycol Other / unclassified — —

Indications

nervous system injury